

# David L Scott

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3448076/david-l-scott-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60  
papers

1,332  
citations

19  
h-index

35  
g-index

69  
ext. papers

1,555  
ext. citations

5.3  
avg, IF

4.85  
L-index

#	Paper	IF	Citations
60	Baseline predictors of remission, pain and fatigue in rheumatoid arthritis: the TITRATE trial. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 278	5.7	2
59	Treat-to-Target Strategies in Rheumatoid Arthritis: a Systematic Review and Cost-Effectiveness Analysis. <i>SN Comprehensive Clinical Medicine</i> , <b>2021</b> , 3, 838-854	2.7	0
58	Intensive therapy for moderate established rheumatoid arthritis: the TITRATE research programme. <i>Programme Grants for Applied Research</i> , <b>2021</b> , 9, 1-186	1.5	0
57	Thromboembolism and Janus Kinase Inhibitors. <i>Drug Safety</i> , <b>2020</b> , 43, 831-833	5.1	5
56	The value, impact and role of nurses in rheumatology outpatient care: Critical review of the literature. <i>Musculoskeletal Care</i> , <b>2020</b> , 18, 245-255	1.6	4
55	A systematic review of guidelines for managing rheumatoid arthritis. <i>BMC Rheumatology</i> , <b>2019</b> , 3, 42	2.9	27
54	Real world long-term impact of intensive treatment on disease activity, disability and health-related quality of life in rheumatoid arthritis. <i>BMC Rheumatology</i> , <b>2019</b> , 3, 6	2.9	12
53	Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?. <i>Drug Safety</i> , <b>2018</b> , 41, 645-653	5.1	94
52	Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 769-778	4.4	5
51	Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 1063-1072	4.4	4
50	Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , <b>2018</b> , 36, 1427-1437	4.4	3
49	Intensive therapy and remissions in rheumatoid arthritis: a systematic review. <i>BMC Musculoskeletal Disorders</i> , <b>2018</b> , 19, 389	2.8	15
48	Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 1515-1521	4.1	18
47	Variable impacts of different remission states on health-related quality of life in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 203-209	2.2	6
46	Participants' Experiences of an Education, self-management and upper extremity eXercise Training for people with Rheumatoid Arthritis programme (EXTRA). <i>Physiotherapy</i> , <b>2017</b> , 103, 430-438	3	7
45	The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 973-980	4.1	13
44	Treating active rheumatoid arthritis with Janus kinase inhibitors. <i>Lancet, The</i> , <b>2017</b> , 390, 431-432	4.0	5

43	Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF- $\alpha$ Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , <b>2017</b> , 35, 1141-1151	4.4	2
42	Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial. <i>Trials</i> , <b>2017</b> , 18, 591	2.8	9
41	Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis-a proof of principle and exploratory trial: is dose tapering practical in good responders?. <i>Rheumatology</i> , <b>2017</b> , 56, 2004-2014	3.9	20
40	The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , <b>2017</b> , 21, 1-258	4.4	27
39	Predicting responses in patients with rheumatoid arthritis to disease-modifying agents using baseline clinical data. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 810-815	2.2	2
38	A systematic review of randomised controlled trials in rheumatoid arthritis: the reporting and handling of missing data in composite outcomes. <i>Trials</i> , <b>2016</b> , 17, 272	2.8	16
37	Beyond methotrexate monotherapy for early rheumatoid arthritis. <i>Lancet, The</i> , <b>2016</b> , 388, 309-310	4.0	
36	Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 142	5.7	5
35	Changing clinical patterns in rheumatoid arthritis management over two decades: sequential observational studies. <i>BMC Musculoskeletal Disorders</i> , <b>2016</b> , 17, 44	2.8	14
34	Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. <i>Rheumatology</i> , <b>2016</b> , 55, 268-78	3.9	128
33	Have radiographic progression rates in early rheumatoid arthritis changed? A systematic review and meta-analysis of long-term cohorts. <i>Rheumatology</i> , <b>2016</b> , 55, 1053-1065	3.9	14
32	Cardiovascular risk with NSAIDs in rheumatoid arthritis: an analysis using routinely collected data. <i>Rheumatology</i> , <b>2016</b> , 55, 763-4	3.9	8
31	A randomised trial evaluating anakinra in early active rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 88-93	2.2	21
30	Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. <i>BMJ, The</i> , <b>2015</b> , 350, h1046	5.9	46
29	Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2015</b> , 16, 77	2.8	24
28	Expectations of new treatment in rheumatoid arthritis: developing a patient-generated questionnaire. <i>Health Expectations</i> , <b>2015</b> , 18, 995-1008	3.7	11
27	Psychometric properties of a new treatment expectation scale in rheumatoid arthritis: an application of item response theory. <i>BMC Musculoskeletal Disorders</i> , <b>2015</b> , 16, 239	2.8	1
26	Assessing the effectiveness of synthetic and biologic disease-modifying antirheumatic drugs in psoriatic arthritis - a systematic review. <i>Psoriasis: Targets and Therapy</i> , <b>2015</b> , 5, 71-81	2.4	3

25	Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 760-70	4.1	67
24	Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. <i>Rheumatology</i> , <b>2015</b> , 54, 1050-5	3.9	17
23	Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis. <i>Rheumatology</i> , <b>2015</b> , 54, 302-9	3.9	12
22	Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?. <i>Drugs</i> , <b>2014</b> , 74, 415-22	12.1	13
21	Clinical and serological predictors of remission in rheumatoid arthritis are dependent on treatment regimen. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1298-303	4.1	10
20	Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. <i>Rheumatology</i> , <b>2014</b> , 53, 1773-7	3.9	19
19	Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 44, 131-44	5.3	46
18	Enhanced and persistent levels of interleukin (IL)-17+ CD4+ T cells and serum IL-17 in patients with early inflammatory arthritis. <i>Clinical and Experimental Immunology</i> , <b>2013</b> , 174, 292-301	6.2	42
17	Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis. <i>Drugs</i> , <b>2011</b> , 71, 1121-32	12.1	27
16	Quality of life and the outcome of established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2011</b> , 25, 585-606	5.3	29
15	Career lifetime advances in rheumatology. <i>Clinical Medicine</i> , <b>2010</b> , 10, 156-9	1.9	
14	Clinical trials: Tight control in early RA pays off in the long run. <i>Nature Reviews Rheumatology</i> , <b>2010</b> , 6, 623-4	8.1	4
13	NICE guidelines on anti-tumor necrosis factor therapy for RA. <i>Nature Clinical Practice Rheumatology</i> , <b>2009</b> , 5, 16-7		5
12	What have we learnt about the development and progression of early RA from RCTs?. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2009</b> , 23, 13-24	5.3	5
11	Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 1102-7	12.3	46
10	Early rheumatoid arthritis. <i>British Medical Bulletin</i> , <b>2007</b> , 81-82, 97-114	5.4	16
9	The course of established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2007</b> , 21, 943-67	5.3	61
8	Outcomes associated with early rheumatoid arthritis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2006</b> , 6, 495-508	2.2	10

7	What are the consequences of early rheumatoid arthritis for the individual?. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2005</b> , 19, 117-36	5.3	66
6	Pursuit of optimal outcomes in rheumatoid arthritis. <i>Pharmacoeconomics</i> , <b>2004</b> , 22, 13-26	4.4	13
5	Radiological progression in established rheumatoid arthritis. <i>Journal of rheumatology Supplement, The</i> , <b>2004</b> , 69, 55-65		35
4	Genotypes and phenotypes: should genetic markers and clinical predictors drive initial treatment decisions in rheumatic diseases?. <i>Current Opinion in Rheumatology</i> , <b>2003</b> , 15, 213-8	5.3	6
3	Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis. <i>BioDrugs</i> , <b>2001</b> , 15, 543-61	7.9	9
2	Choice of NSAID and management strategy in rheumatoid arthritis and osteoarthritis. The impact on costs and outcomes in the UK. <i>Pharmacoeconomics</i> , <b>1998</b> , 14, 191-9	4.4	13
1	Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation. <i>Arthritis and Rheumatism</i> , <b>1996</b> , 39, 1998-2003		137